Fig. 2. Stratification of prostate cancer samples based on the percentage of DESNT cancer present.
For these analyses, the data from the MSKCC, CancerMap, CamCap and Stephenson datasets were combined (n = 503). a Plot showing the proportion of DESNT signature in each cancer sample, and the division into four groups of increasing DESNT. Group 1 samples have a proportion of <0.001 of the DESNT signature. b Kaplan–Meier plot showing the biochemical recurrence (BCR)-free survival based on the proportion of DESNT cancer present, as determined by LPD. The number of cancer patients in each group are indicated (bottom right), and the number of PCR failures in each group are shown in parentheses. The definition of Groups 1–4 is shown in Fig. 2a. Cancer samples with proportions up to 0.3 DESNT (Group 2) exhibited poorer clinical outcome (χ2 test, P = 0.011) compared with cancer samples lacking DESNT (<0.001). Cancer samples with the intermediate (0.3–0.6) and high (>0.6) proportions of DESNT also exhibited significantly worse outcome (P = 2.6 × 10−5 and P = 8.3 × 10−9, respectively, compared with cancer samples lacking DESNT. The combined log-rank P = 1.3 × 10–8). c Nomogram model developed to predict PSA-free survival at 1, 3, 5 and 7 years using proportion of DESNT. Assessing each clinical variable in a single patient has a corresponding point score (top scales). The point scores for each variable are added to produce a total point score for each patient. The predicted probability of PSA-free survival at 1, 3, 5 and 7 years, can be determined by drawing a vertical line from the total point score to the probability scales below.